| A Study of PN20 in Healthy Adult Volunteers (NCT06523088) | Chongqing Peg-Bio Biopharm Co., Ltd. | 2022-06-16 |
| A Clinical Study of Hetrombopag Olamine Tablets in Adults Receiving 21-day Cycles of Chemotherapy for Solid Tumours, Who Are Delayed for at Least 1 Week From Their Scheduled Cycle Because of Chemotherapy-induced Thrombocytopenia (NCT05261646) | Jiangsu HengRui Medicine Co., Ltd. | 2022-04-15 |
| Herombopag for Chemotherapy-induced Thrombocytopenia (NCT05236582) | Institute of Hematology & Blood Diseases Hospital, China | 2022-03-14 |
| Avatrombopag for Chemotherapy-induced Thrombocytopenia (NCT05218226) | Institute of Hematology & Blood Diseases Hospital, China | 2022-02-10 |
| Evaluating the Efficacy and Safety of QL0911 in Chemotherapy- Induced Thrombocytopenia (NCT05851027) | Qilu Pharmaceutical Co., Ltd. | 2021-01-15 |
| Eltrombopag for Chemotherapy-induced Thrombocytopenia (NCT04600960) | Institute of Hematology & Blood Diseases Hospital, China | 2020-12-31 |
| To Evaluate Thrombosis Risk in Chemotherapy Patients With Solid Tumors Who Receiving Thrombocytopenia Treatment (NCT05688306) | Liaoning Cancer Hospital & Institute | 2020-09-02 |
| Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer (NCT03937154) | Amgen | 2020-02-26 |
| Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Malignancy. (NCT03976882) | Jiangsu HengRui Medicine Co., Ltd. | 2019-11-06 |
| Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer (NCT03362177) | Amgen | 2019-09-30 |
| Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological Cancers (NCT03471078) | Sobi, Inc. | 2018-10-12 |
| Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Lymphoma. (NCT03343847) | Amgen | 2018-01-27 |
| A Study of the Recombinant Human Interleukin-11 (I) (Baijieyi) for Prevention and Treatment of Chemotherapy-induced Thrombocytopenia in Patients With Malignant Tumor (NCT03049774) | Angde Biotech Pharmaceutical Co., Ltd. | 2017-02-28 |
| A Phase Ⅲa Study of Genetically Modified Recombinant Human Interleukin-11 (NCT01663441) | Beijing Northland Biotech. Co., Ltd. | 2015-03-01 |
| Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias. (NCT01933035) | Beth Israel Medical Center | 2013-10-01 |
| A Study of the Safety and Efficacy of ONO-7746 in Adult Cancer Patients With Chemotherapy Induced Thrombocytopenia (NCT01345214) | Ono Pharma USA Inc | 2011-05-01 |
| Application of AS101 for the Treatment of Thrombocytopenia in Solid Tumor Patients (NCT00926354) | BioMAS Ltd | 2009-08-01 |
| Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC) (NCT00413283) | Amgen | 2006-12-01 |
| A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma (NCT00283439) | Amgen | 2005-10-01 |